A Study on Clinical and Pathological Responses to Neoadjuvant Chemotherapy in Breast Carcinoma

References

• OlivottoIA, ChuaB, AllanSJ, et al. Long-term survival of patients with supraclavicular metastases at diagnosis of breast cancer. J Clin Oncol. 2003;21:851–854. doi:10.1200/JCO.2003.11.10512610184
   PubMed Web of Science ®Google Scholar
• BritoRA, ValeroV, BuzdarAU, et al. Long-term results of combined modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastasis: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001;19:628–633. doi:10.1200/JCO.2001.19.3.62811157012
   PubMed Web of Science ®Google Scholar
• SingletarySE, AllredC, AhsleyP, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628–3636. doi:10.1200/JCO.2002.02.02612202663
   PubMed Web of Science ®Google Scholar
• KolscienlyS, TubianaM, LeMG, et al. Breast cancer: relationship between the size of the primary tumor and the probability of metastatic dissemination. Br J Cancer. 1984;49:709–715. doi:10.1038/bjc.1984.1126733019
   PubMed Web of Science ®Google Scholar
• WaljeeJF, NewmanLA. Surg Clin N Am. 2007;87:399–415. doi:10.1016/j.suc.2007.02.00417498534
   PubMed Web of Science ®Google Scholar
• SwainSM, SoraceRA, BagleyCS, et al. NACT in the combined modality approach of LABC. Cancer Res. 1987;47:3889–3894.3036348
   PubMed Web of Science ®Google Scholar
• CarterCL, AllenC, HensenDE. Relation of Tumor size, lymph node station and survival in 24, 740 breast cancer cases. Cancer. 1989;63:181–187.2910416
   PubMed Web of Science ®Google Scholar
• ValagassaP, ZumbettuM, BigmaP, et al. T3b-T4 breast cancer factors affecting results in combined modality treatment. Clin Exp Metastasis. 1983;1::191–202. doi:10.1007/BF001214986400435
   PubMed Web of Science ®Google Scholar
• SemiglazovVF, TopuzovEE, BavliJL, et al. Primary chemotherapy & Radiotherapy compared with primary radiotherapy above in Stage IIb – iIIa breast carcinoma. Ann Oncol. 1994;5:591–595. doi:10.1093/oxfordjournals.annonc.a0589297993833
   PubMed Web of Science ®Google Scholar
• VanderHgeJA, VendeveldeCJ, JulienJP, et al. Preoperative chemotherapy in primary operable breast cancer results from the European organization for research and treatment of cancer trial 10902. J Clin Oncol. 2001;19::4224–4237. doi:10.1200/JCO.2001.19.22.422411709566
   PubMed Web of Science ®Google Scholar
• KayalS, BiswajitD, CyriacSL, et al. Comparison of neoadjuvant chemotherapy (NACT) with 5-fluorouracil, epirubicin (100mg), cyclophosphamide (FEC100) followed by docetaxel (D) (75mg) versus adriamycin and cyclophosphamide (AC) followed by docetaxel (100mg) in locally advanced breast cancer (LABC): a randomized clinical study. J Clin Oncol. 33(15_suppl). doi:10.1200/jco.2015.33.15_suppl.e12002
   Web of Science ®Google Scholar
• BuzdarA, SumanVJ, Meric-BernstamF, et al. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast ca. J Clin Oncol. 2013;31(15_suppl):502. doi:10.1200/jco.2013.31.15_suppl.502
   Web of Science ®Google Scholar
• KaufmannM, HortobagyiGN, GoldhirschA, et al. von Minckwitz G: recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–1949. doi:10.1200/JCO.2005.02.618716622270
   PubMed Web of Science ®Google Scholar
• SorlieT, TibshiraniR, ParkerJ, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418–8423. doi:10.1073/pnas.093269210012829800
   PubMed Web of Science ®Google Scholar
• EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247
   Google Scholar
• Fernandez-SanchezM, Gamboa-DominguezA, UribeN, et al. Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Med Oncol. 2006;23(2):171–183. doi:10.1385/MO:23:2:17116720917
   PubMed Web of Science ®Google Scholar
• SchwartzG. Neoadjuvant induction chemotherapy. Minerva Ginecol. 2005;57(3):327–348.16166939
   PubMedGoogle Scholar
• CharfareH, LimongelliS, PurushothamAD. Neoadjuvant chemotherapy in breast cancer. Br J Surg. 2005;92(1):14–23. doi:10.1002/bjs.484015635596
   PubMed Web of Science ®Google Scholar
• Alvarado-CabreroI, Alderete-VazquezG, Quintal- RamirezM, PatinoM, RuizE. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: cor- relation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Ann Diagn Pathol. 2009;13(3):151–157.19433292
   PubMed Web of Science ®Google Scholar
• OlfaaG, AmelbT, RimaC, et al. Clinical and pathological response to neoadjuvant anthracy- cline based chemotherapy in women with breast cancer. World J Oncol. 2010;1(4):167–17211.29147200
   PubMedGoogle Scholar
• Del PreteS, et al. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: a single center experience. Oncol Lett. 2019;18(4):3873–3879. doi:10.3892/ol.2019.1072931516598
   PubMed Web of Science ®Google Scholar
• MigliettaL, et al. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki. Anticancer Res. 2009;29(5):1621–1625.19443376
   PubMed Web of Science ®Google Scholar
• ResendeU, CabelloC, RamalhoSOB, et al. Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response. BMC Cancer. 2019;19:601. doi:10.1186/s12885-019-5812-031208353
   PubMed Web of Science ®Google Scholar
• AlawadAAM. Evaluation of clinical and pathological response after two cycles of neoadjuvant chemotherapy on sudanese patients with locally advanced breast cancer. Ethiop J Health Sci. 2014;24(1):15–20. doi:10.4314/ejhs.v24i1.2
   Google Scholar
• BeresfordMJ, StottD, MakrisA. Assessment of clinical response after two cycles of primary chemotherapy in breast cancer. Breast Cancer Res Treat. 2008;109:5. doi:10.1007/s10549-007-9644-2
   Web of Science ®Google Scholar
• RastogiP, AndersonSJ, BearHD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–785. doi:10.1200/JCO.2007.15.023518258986
   PubMed Web of Science ®Google Scholar
• MaurM, GuarneriV, FrassoldatiA, ContePF. Primary systemic therapy in operable breast cancer: clinical data and biological fall-out. Ann Oncol. 2006;17:158–164. doi:10.1093/annonc/mdj973
   Web of Science ®Google Scholar
• BurcombeRJ, MakrisA, RichmanPI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005;92:147–155. doi:10.1038/sj.bjc.660225615611798
   PubMed Web of Science ®Google Scholar
• Kim.SI, Sohn.J, Koo.JS, ParkSH, ParkBW. Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer-clinical translational research. Oncology. 2010;79:324–330. doi:10.1159/00032219221430399
   PubMed Web of Science ®Google Scholar
• GianniL, EiermannW, SemiglazovV, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 2010;375:377–384.20113825
   PubMed Web of Science ®Google Scholar
• PhungHT, NguyenHT, Van NguyenT, Van NguyenT, Thi DinhLA, Van NguyenC. Pathological complete response with neoadjuvant trastuzumab combined with Chemotherapy in HER2 positive breast cancer: a single institution retrospective analysis from vietnam. Breast Cancer. 2020;12:117–122.33116813
   PubMed Web of Science ®Google Scholar